Day One Biopharmaceuticals Files Pro Forma Financials for Mersana Acquisition

summarizeSummary

Day One Biopharmaceuticals filed an amended 8-K to include audited and unaudited financial statements of Mersana Therapeutics, Inc. and pro forma combined financial information following the acquisition completed on January 6, 2026.

check_boxKey Events

• Provides Financials for Mersana Acquisition

  The filing includes audited financial statements for Mersana Therapeutics for 2023 and 2024, and unaudited interim financials for the three and nine months ended September 30, 2025, as required for the completed acquisition.

• Details Pro Forma Combined Financials

  Unaudited pro forma condensed combined financial information for Day One and Mersana is presented for the nine months ended September 30, 2025, and the year ended December 31, 2024, illustrating the financial impact of the merger.

• Acquisition Valued at $173 Million

  The preliminary purchase price for Mersana Therapeutics was $173.0 million, consisting of $125.0 million in cash and $48.0 million in estimated fair value of contingent value rights (CVRs).

• Recognizes Goodwill and Intangibles

  The acquisition resulted in the recognition of $36.7 million in goodwill and $196.8 million in identifiable intangible assets, including a contract-based license asset and an in-process research and development (IPR&D) asset.

auto_awesomeAnalysis

This 8-K/A provides crucial financial details regarding Day One Biopharmaceuticals' acquisition of Mersana Therapeutics, Inc., which closed on January 6, 2026. The filing includes Mersana's historical financial statements and the unaudited pro forma condensed combined financial information, allowing investors to assess the financial impact of the integration. The preliminary purchase price was $173.0 million, including cash and contingent value rights, representing a significant strategic expansion of Day One's oncology pipeline. The pro forma financials illustrate the combined entity's financial position and operating results as if the acquisition had occurred earlier, which is essential for understanding the company's post-merger financial health.